Want to join the conversation?
Medical devices maker $VAR said that it is supporting a Phase III trial "Stablemates Trial", a trial for the treatment of early-stage, high-risk, operable non-small cell lung cancer. This study is being administered by the Department of Radiation Oncology at the University of Texas Southwestern Medical Center, the company said.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.